Sveriges mest populära poddar
Short Wave
Short Wave

FDA Approves Aducanumab — A Controversial Drug For Alzheimer's

12 min•25 juni 2021

Om avsnittet

The FDA has approved a new drug for Alzheimer's. But a lot of experts are skeptical about whether the drug works. Rhitu Chatterjee talks with science correspondent Jon Hamilton about the controversial drug aducanumab and why the U.S. Food and Drug Administration approved it.

For more of Jon's reporting, read "For Those Facing Alzheimer's, A Controversial Drug Offers Hope."

You can email Short Wave at [email protected].

See pcm.adswizz.com for information about our collection and use of personal data for sponsorship and to manage your podcast sponsorship preferences.

NPR Privacy Policy

Short Wave med NPR finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.